A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease
Status:
Terminated
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will compare the efficacy of intravenous Bondronat with that of zoledronic
acid in patients with malignant bone disease experiencing moderate to severe pain. Patients
will be randomized to receive either Bondronat (6mg iv on days 1, 2 and 3 and then every 3-4
weeks) or zoledronic acid (4mg iv on day 1 and then every 3-4 weeks). The anticipated time of
study treatment is 6-12 months, and the target sample size is 100-500 individuals.